Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Ablynx [Euronext Brussels: ABLX] announced today detailed results from the open label extension of the Phase Ib study of its anti-thrombotic, ALX-0081, in patients with stable angina undergoing percutaneous coronary intervention (PCI). read more
Dit artikel is verschenen in Medinews.
Klik hier om het volledige artikel te lezen. read more
This article was spread by Reuters Agency.
To read the full article, click here. read more
Dit artikel is verschenen in De Tijd.
Klik hier om het volledige artikel te lezen. read more
Dit artikel is verschenen in De Tijd.
Klik hier om het volledige artikel te lezen. read more
Dit artikel is verschenen in De Tijd.
Klik hier om het volledige artikel te lezen. read more
Movetis announces today that Credit Suisse and KBC Securities, acting as Joint Global Coordinators and on behalf of the bank syndicate, have fully exercised the Over-allotment Option, in accordance with provisions contained in the initial public offering (IPO) prospectus. read more
Dit artikel is verschenen in De Tijd.
Klik hier om het volledige artikel te lezen. read more
Dit artikel is verschenen in De Tijd.
Klik hier om het artikel te lezen. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease. read more
